Peptide IGF-1 LR3 de qualit\u00e9 r\u00e9cepteur<\/strong> is a synthetic analog of insulin-like growth factor-1 (IGF-1), a naturally occurring 70-amino-acid protein involved in cellular growth, development, metabolism, and signaling. Researchers developed IGF-1 Long R3 by extending the N-terminal region of IGF-1 by 13 amino acids and replacing glutamic acid at position 3 with arginine.<\/p>\n These structural modifications distinguish IGF-1 LR3 from endogenous IGF-1 and have been studied for their effects on receptor interactions, binding-protein affinity, tissue distribution, and cellular signaling.<\/p>\n The term Receptor Grade<\/strong> describes a higher-purity research material intended for receptor- and cell-based laboratory applications. It does not indicate clinical approval or therapeutic status.<\/p>\n Receptor Grade IGF-1 LR3 is a modified form of human IGF-1 containing an N-terminal extension and an arginine substitution at residue 3. Researchers study this analog because its structural modifications can alter interactions with IGF-binding proteins (IGFBPs), receptor signaling, and experimental tissue distribution.<\/p>\n IGF-1 research commonly examines pathways associated with cellular proliferation, differentiation, metabolism, protein synthesis, and survival.<\/p>\n IGF-1 belongs to a family of growth factors that share structural similarities with insulin. In biological systems, IGF-1 primarily interacts with the insulin-like growth factor-1 receptor (IGF-1R), a receptor tyrosine kinase involved in intracellular signaling.<\/p>\n Following receptor activation, downstream pathways can include:<\/p>\n IGF-1 LR3 has attracted research interest because its modified structure appears to reduce its interaction with certain IGF-binding proteins compared with endogenous IGF-1. Researchers have consequently investigated whether this structural difference changes receptor availability, biological activity, and tissue distribution in experimental systems.<\/p>\n For related growth-factor research, researchers may also investigate Peptide MGF<\/a> et Follistatine-344<\/a> as distinct research compounds with different molecular targets.<\/p>\n The primary research focus involves interaction with the IGF-1 receptor (IGF-1R)<\/strong>. IGF-1R is located on the surface of numerous cell types and functions as a receptor tyrosine kinase.<\/p>\n When activated, IGF-1R can initiate intracellular signaling networks involving PI3K\/Akt and MAPK\/ERK. These pathways participate in processes such as:<\/p>\n The exact magnitude and biological consequences of these signals depend on the experimental model, receptor expression, peptide concentration, and cellular environment.<\/p>\n One distinguishing feature of IGF-1 LR3 research is its altered interaction with IGF-binding proteins (IGFBPs)<\/strong>.<\/p>\n Endogenous IGF-1 normally circulates in association with IGFBPs, which can influence its stability, transport, receptor availability, and tissue distribution. Researchers have investigated whether the structural modifications in IGF-1 LR3 reduce this binding and consequently alter the peptide’s experimental bioavailability.<\/p>\n IGF-1 receptor signaling can activate multiple intracellular pathways.<\/p>\n Le PI3K\/Akt pathway<\/strong> participates in cellular metabolism, protein synthesis, and survival signaling. Meanwhile, the MAPK\/ERK pathway<\/strong> is associated with cellular proliferation, differentiation, and gene-expression regulation.<\/p>\n These pathways provide an important mechanistic framework for understanding why IGF-1 analogs remain relevant to laboratory research involving growth-factor biology.<\/p>\n The molecular structure distinguishes IGF-1 LR3 from endogenous IGF-1 and provides the basis for ongoing research into receptor interaction and IGFBP binding.<\/p>\n Researchers have investigated modified IGF-1 analogs to determine whether structural changes can produce different biological activity from endogenous IGF-1.<\/p>\n Preclinical experiments compared IGF-1 LR3 with IGF-I in normal and experimentally induced catabolic animal models. Researchers evaluated parameters including body weight, visceral organ weight, feed utilization, and markers associated with protein breakdown.<\/p>\n The supplied research describes IGF-1 LR3 as exhibiting greater anabolic activity than IGF-I across several experimental measurements. In dexamethasone-exposed models, the peptide was also associated with a greater reduction in N\u03c4-methylhistidine excretion, a laboratory marker associated with muscle protein breakdown.<\/p>\n These findings provide a basis for continued investigation of modified IGF-1 analogs in experimental growth-factor and protein-metabolism research. However, animal-model findings cannot establish equivalent effects in humans.<\/p>\n IGF-1 has been extensively investigated for its relationship with cellular growth and development.<\/p>\n Researchers have examined IGF-1 signaling in models involving altered or deficient IGF-1 activity.<\/p>\n Experimental models were evaluated following exposure to IGF-1, with growth parameters compared against control conditions.<\/p>\n The research described increased growth and total length in peptide-exposed models compared with controls.<\/p>\n These findings reinforce the importance of the IGF-1 signaling system in experimental studies of growth and development. They also provide context for investigating modified analogs such as IGF-1 LR3.<\/p>\n Researchers have investigated how IGF-family proteins influence glucose uptake and metabolic signaling.<\/p>\n IGF-1 receptor activation can interact with intracellular pathways such as PI3K and AMPK that participate in glucose metabolism.<\/p>\n Research has also explored whether modified IGF analogs can influence glucose uptake through mechanisms extending beyond conventional IGF-1 receptor signaling.<\/p>\n This work makes IGF-1 LR3 relevant to laboratory investigations involving growth-factor signaling, insulin sensitivity pathways, and cellular metabolism.<\/p>\n Importantly, these findings do not establish IGF-1 LR3 as a treatment for insulin resistance, diabetes, or any metabolic disorder.<\/p>\n Researchers have examined the relationship between growth-hormone\/IGF signaling and age-associated cellular changes.<\/p>\n Experimental animal models were evaluated for physiological and neurological changes following exposure to IGF-related compounds.<\/p>\n The supplied research describes observations involving muscle and neurological function in experimental models.<\/p>\n These findings illustrate the complexity of IGF signaling across different stages of biological aging. Researchers continue to investigate how growth-factor pathways interact with cellular maintenance, metabolism, and age-related physiological changes.<\/p>\n Researchers have examined IGF-1 analogs in relation to myostatin-associated signaling and muscle-cell biology.<\/p>\n Animal models were exposed to IGF-1 analogs, including IGF-1 LR3, and researchers evaluated pathways associated with myostatin activity, cellular differentiation, and apoptosis.<\/p>\n The supplied research suggests that IGF-1 analogs may influence myostatin-associated signaling and cellular survival in experimental models.<\/p>\n Myostatin is a growth-regulating protein that researchers study extensively in relation to skeletal-muscle differentiation and development. Consequently, IGF-1 LR3 remains relevant to laboratory investigations of growth-factor and muscle-cell signaling.<\/p>\n For comparison with other compounds studied in muscle-related molecular research, see MGF<\/a> et Follistatine-344<\/a>.<\/p>\n Researchers have compared the pharmacokinetic and tissue-distribution characteristics of IGF-1 LR3 with endogenous IGF-1.<\/p>\n Experimental mouse models received labeled IGF-1 LR3, after which researchers evaluated peptide clearance and tissue localization.<\/p>\n The research described relatively rapid serum clearance of IGF-1 LR3 alongside detectable distribution in tissues including the kidneys, ovaries, and adrenal glands.<\/p>\n Researchers attributed some of these differences to the modified peptide’s reduced interaction with IGFBPs.<\/p>\n The findings demonstrate how relatively small structural modifications can influence peptide distribution and binding characteristics.<\/p>\n The primary difference is structural. IGF-1 LR3 contains a 13-amino-acid N-terminal extension and replaces glutamic acid at position 3 with arginine.<\/p>\n These modifications may alter:<\/p>\n Therefore, IGF-1 LR3 should be considered a distinct research analog rather than simply another form of endogenous IGF-1.<\/p>\n Research involving IGF-1 LR3 focuses on potential biological effects rather than established therapeutic benefits.<\/p>\n Areas of scientific interest include:<\/p>\n The available evidence is predominantly preclinical, and the supplied research does not establish clinical efficacy or safety in humans.<\/p>\n IGF-1 LR3 belongs to a broader category of research compounds involving growth-factor and cellular-signaling pathways.<\/p>\n Par exemple:<\/p>\n These compounds should not be considered interchangeable because they interact with different molecular targets and signaling systems.<\/p>\n Receptor Grade IGF-1 LR3 is a synthetic analog of IGF-1 containing a 13-amino-acid N-terminal extension and an arginine substitution at position 3. Researchers study it primarily in growth-factor, receptor-signaling, and cellular biology applications.<\/p>\n Research suggests IGF-1 LR3 can interact with IGF-related signaling systems, including IGF-1 receptor pathways. Its modified structure also appears to alter interactions with IGF-binding proteins.<\/p>\n IGF-1 LR3 research includes cellular growth, differentiation, protein metabolism, glucose signaling, muscle-cell biology, receptor signaling, and tissue-distribution studies.<\/p>\n IGF-1 LR3 contains an N-terminal extension and an Arg3 substitution. These structural modifications can alter its binding characteristics, tissue distribution, and behavior in experimental systems.<\/p>\n This research material should not be represented as FDA-approved. The product is supplied for laboratory and research applications only.<\/p>\nWhat Is Receptor Grade IGF-1 LR3?<\/h2>\n
Aper\u00e7u<\/h2>\n
\n
Receptor Grade IGF-1 LR3 Mechanism of Action<\/h2>\n
IGF-1 Receptor Signaling<\/h3>\n
\n
IGF-Binding Proteins<\/h3>\n
PI3K\/Akt and MAPK\/ERK Pathways<\/h3>\n
\nComposition chimique<\/h2>\n
\n\n
\n \nProperty<\/th>\n IGF-1 LR3 de qualit\u00e9 r\u00e9cepteur<\/th>\n<\/tr>\n<\/thead>\n \n Molecular Formula<\/td>\n C400H625N111O115S9<\/td>\n<\/tr>\n \n Molecular Weight<\/td>\n 9117.5 g\/mol<\/td>\n<\/tr>\n \n Type de peptide<\/td>\n Synthetic IGF-1 analog<\/td>\n<\/tr>\n \n Parent Molecule<\/td>\n Insulin-like Growth Factor-1<\/td>\n<\/tr>\n \n Structural Modification<\/td>\n 13-amino-acid N-terminal extension + Arg substitution at position 3<\/td>\n<\/tr>\n \n Autres noms<\/td>\n Long-(Arg3) IGF-I; IGF-1 Long R3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\nRecherche et \u00e9tudes cliniques<\/h2>\n
Receptor Grade IGF-1 LR3 and Anabolic Signaling Research<\/h2>\n
Objectif de l'\u00e9tude<\/h3>\n
M\u00e9thodologie<\/h3>\n
R\u00e9sultats<\/h3>\n
Importance scientifique<\/h3>\n
\nReceptor Grade IGF-1 LR3 and Cellular Growth Research<\/h2>\n
Objectif de l'\u00e9tude<\/h3>\n
M\u00e9thodologie<\/h3>\n
R\u00e9sultats<\/h3>\n
Importance scientifique<\/h3>\n
\nReceptor Grade IGF-1 LR3 and Glucose Uptake Research<\/h2>\n
Objectif de l'\u00e9tude<\/h3>\n
Mechanism Investigated<\/h3>\n
Importance scientifique<\/h3>\n
\nReceptor Grade IGF-1 LR3 and Cellular Longevity Research<\/h2>\n
Objectif de l'\u00e9tude<\/h3>\n
M\u00e9thodologie<\/h3>\n
R\u00e9sultats<\/h3>\n
Importance scientifique<\/h3>\n
\nReceptor Grade IGF-1 LR3 and Muscle-Cell Research<\/h2>\n
Objectif de l'\u00e9tude<\/h3>\n
M\u00e9thodologie<\/h3>\n
R\u00e9sultats<\/h3>\n
Importance scientifique<\/h3>\n
\nReceptor Grade IGF-1 LR3 and Tissue Distribution<\/h2>\n
Objectif de l'\u00e9tude<\/h3>\n
M\u00e9thodologie<\/h3>\n
R\u00e9sultats<\/h3>\n
Importance scientifique<\/h3>\n
\nWhat Makes Receptor Grade IGF-1 LR3 Different From IGF-1?<\/h2>\n
\n
\nReceptor Grade IGF-1 LR3 Benefits Research<\/h2>\n
\n
\nReceptor Grade IGF-1 LR3 vs. Other Growth-Factor Peptides<\/h2>\n
\n
\nFoire aux questions<\/h2>\n
What is Receptor Grade IGF-1 LR3?<\/h3>\n
How does Receptor Grade IGF-1 LR3 work?<\/h3>\n
What is Receptor Grade IGF-1 LR3 researched for?<\/h3>\n
What makes IGF-1 LR3 different from IGF-1?<\/h3>\n
Is Receptor Grade IGF-1 LR3 FDA approved?<\/h3>\n
\nConclusion<\/h2>\n